Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment

Psychoneuroendocrinology

Volumn 65, Issue , 2016, Pages 67-75

  Chen, Chun Yen ^a,b   Yeh, Yi Wei ^b   Kuo, Shin Chang ^a,b   Ho, Pei Shen ^b   Liang, Chih Sung ^a,b   Yen, Che Hung ^a,b   Lu, Ru Band ^c   Huang, San Yuan ^a,b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Amisulpride; Catechol O methyltransferase gene; Negative symptom; Prolactin; Response; Schizophrenia

Indexed keywords

AMISULPRIDE; CATECHOL METHYLTRANSFERASE; PROLACTIN; COMT PROTEIN, HUMAN; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

ADULT; ARTICLE; CHINESE; COMT GENE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLACTIN; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME;

EID: 84958162783     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.12.003     Document Type: Article

References (40)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders. Text Revision 2000, American Psychiatric Association, Washington, DC. fourth ed.
2. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
3. Bertolino A., Caforio G., Blasi G., Rampino A., Nardini M., Weinberger D.R., Dallapiccola B., Sinibaldi L., Douzgou S. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr. Res. 2007, 95:253-255.
4. Bosia M., Zanoletti A., Spangaro M., Buonocore M., Bechi M., Cocchi F., Pirovano A., Lorenzi C., Bramanti P., Smeraldi E., Cavallaro R. Factors affecting cognitive remediation response in schizophrenia: the role of COMT gene and antipsychotic treatment. Psychiatry Res. 2014, 217:9-14.
5. Bressan R.A., Erlandsson K., Jones H.M., Mulligan R., Flanagan R.J., Ell P.J., Pilowsky L.S. Is regionally selective D2/D3 dopamine occupancy sufficient for a typical antipsychotic effect? an in vivo quantitative [123I] epidepride SPET study of amisulpride-treated patients. Am. J. Psychiatry 2003, 160:1413-1420.
6. Chen J., Lipska B.K., Halim N., Ma Q.D., Matsumoto M., Melhem S., Kolachana B.S., Hyde T.M., Herman M.M., Apud J., Egan M.F., Kleinman J.E., Weinberger D.R. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am. J. Hum. Genet. 2004, 75:807-821.
7. Chen C.Y., Lu R.B., Yeh Y.W., Shih M.C., Huang S.Y. Association study of catechol-O-methyltransferase gene polymorphisms with schizophrenia and psychopathological symptoms in Han Chinese. Genes Brain Behav. 2011, 10:316-324.
8. Coello K., Broberg B.V., Bak N., Madsen A., Mortensen H.B., Sogaard B., Szecsi P.B., Knop F.K., Lublin H., Ebdrup B.H. Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. Psychoneuroendocrinology 2015, 60:1-6.
9. Davis K.L., Kahn R.S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148:1474-1486.
10. Endicott J., Spitzer R.L. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch. Gen. Psychiatry 1978, 35:837-844.
11. Furukawa T.A., Levine S.Z., Tanaka S., Goldberg Y., Samara M., Davis J.M., Cipriani A., Leucht S. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry 2015, 72:14-21.
12. Gabriel S.B., Schaffner S.F., Nguyen H., Moore J.M., Roy J., Blumenstiel B., Higgins J., DeFelice M., Lochner A., Faggart M., Liu-Cordero S.N., Rotimi C., Adeyemo A., Cooper R., Ward R., Lander E.S., Daly M.J., Altshuler D. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229.
13. Gao S., Hu Z., Cheng J., Zhou W., Xu Y., Xie S., Liu S., Li Z., Guo J., Dong J., Huang M. Impact of catechol-O-methyltransferase polymorphisms on risperidone treatment for schizophrenia and its potential clinical significance. Clin. Biochem. 2012, 45:787-792.
14. Gupta M., Bhatnagar P., Grover S., Kaur H., Baghel R., Bhasin Y., Chauhan C., Verma B., Manduva V., Mukherjee O., Purushottam M., Sharma A., Jain S., Brahmachari S.K., Kukreti R. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 2009, 10:385-397.
15. Heun R., Ahokas A., Boyer P., Gimenez-Montesinos N., Pontes-Soares F., Olivier V. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J. Clin. Psychiatry 2013, 74:587-594.
16. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Valli I., Tabraham P., Bramon-Bosch E., Valmaggia L., Johns L., Broome M., McGuire P.K., Grasby P.M. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66:13-20.
17. Huang S.Y., Lin W.W., Ko H.C., Lee J.F., Wang T.J., Chou Y.H., Yin S.J., Lu R.B. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin. Exp. Res. 2004, 28:374-384.
18. Huang S.Y., Lin W.W., Wan F.J., Chang A.J., Ko H.C., Wang T.J., Wu P.L., Lu R.B. Monoamine oxidase-polymorphisms might modify the association between the dopamine D2 receptor gene and alcohol dependence. J. Psychiatry Neurosci. 2007, 32:185-192.
19. Huang S.Y., Chen H.K., Ma K.H., Shy M.J., Chen J.H., Lin W.C., Lu R.B. Association of promoter variants of human dopamine transporter gene with schizophrenia in Han Chinese. Schizophr. Res. 2010, 116:68-74.
20. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
21. Kim E.Y., Kim S.H., Lee N.Y., Jung D.C., Kim Y.S., Ahn Y.M. Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Pharmacopsychiatry 2012, 45:57-63.
22. Kotan Z., Ertepe B., Akkaya C., Sarandol E., Ozkaya G., Kirli S. Metabolic:endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study. Ther. Adv. Psychopharmacol. 2011, 1:189-196.
23. Lee S.G., Joo Y., Kim B., Chung S., Kim H.L., Lee I., Choi B., Kim C., Song K. Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum. Genet. 2005, 116:319-328.
24. Leucht S., Cipriani A., Spineli L., Mavridis D., Orey D., Richter F., Samara M., Barbui C., Engel R.R., Geddes J.R., Kissling W., Stapf M.P., Lassig B., Salanti G., Davis J.M. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-962.
25. Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J. Clin. Psychiatry 2014, 75(Suppl 1):8-14.
26. Liu L.C., Hedeker D. A mixed-effects regression model for longitudinal multivariate ordinal data. Biometrics 2006, 62:261-268.
27. Malik P., Kemmler G., Hummer M., Riecher-Roessler A., Kahn R.S., Fleischhacker W.W. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J. Clin. Psychopharmacol. 2011, 31:274-280.
28. Merikangas K.R., Stevens D.E., Fenton B., Stolar M., O'Malley S., Woods S.W., Risch N. Co-morbidity and familial aggregation of alcoholism and anxiety disorders. Psychol. Med. 1998, 28:773-788.
29. Meyer-Lindenberg A., Nichols T., Callicott J.H., Ding J., Kolachana B., Buckholtz J., Mattay V.S., Egan M., Weinberger D.R. Impact of complex genetic variation in COMT on human brain function. Mol Psychiatry 2006, 11:867-877. 797.
30. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 2005, 10:79-104.
31. Molero P., Ortuno F., Zalacain M., Patino-Garcia A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J. 2007, 7:418-426.
32. Neuhaus A.H., Opgen-Rhein C., Urbanek C., Hahn E., Ta T.M., Seidelsohn M., Strathmann S., Kley F., Wieseke N., Sander T., Dettling M. COMT Val 158 Met polymorphism is associated with cognitive flexibility in a signal discrimination task in schizophrenia. Pharmacopsychiatry 2009, 42:141-144.
33. Panizzutti R., Hamilton S.P., Vinogradov S. Genetic correlate of cognitive training response in schizophrenia. Neuropharmacology 2013, 64:264-267.
34. Schlosser R., Grunder G., Anghelescu I., Hillert A., Ewald-Grunder S., Hiemke C., Benkert O. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002, 46:33-40.
35. Stram D.O. Tag SNP selection for association studies. Genet. Epidemiol. 2004, 27:365-374.
36. Tunbridge E.M., Harrison P.J., Weinberger D.R. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol. Psychiatry 2006, 60:141-151.
37. Weickert T.W., Goldberg T.E., Mishara A., Apud J.A., Kolachana B.S., Egan M.F., Weinberger D.R. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 2004, 56:677-682.
38. Yasui-Furukori N., Saito M., Tsuchimine S., Nakagami T., Sato Y., Sugawara N., Kaneko S. Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1491-1495.
39. Zhang X.Y., Zhou D.F., Yuan C.L., Zhang P.Y., Wu G.Y., Shen Y.C. Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res. 2002, 109:297-302.
40. Zhao Q.Z., Liu B.C., Zhang J., Wang L., Li X.W., Wang Y., Ji J., Yang F.P., Wan C.L., Xu Y.F., Feng G.Y., He L., He G. Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatry Genet. 2012, 22:298-299.